GRI Bio to Unveil Phase 2a IPF Data at ERS 2026: Lung Function, Biomarkers, Tolerability
GRI sits 25% above its 52-week low of $1.36.
Summary
GRI Bio will present late-breaking Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis at the European Respiratory Society Congress on September 6, 2026. The company says the data show positive effects on lung function (FVC), anti-fibrotic biomarkers, and favorable tolerability. This is the first detailed look at the Phase 2a results, which could validate the drug's mechanism and support advancement to later-stage trials. The announcement follows the FDA Orphan Drug Designation granted in June 2026 and comes amid a going concern warning and material weakness disclosed in the Q2 10-Q. The oral presentation is scheduled for 3:45 PM CEST on September 6; the market will react to the actual data, not just the announcement.
At the time of this announcement, GRI was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $1.36 to $80.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.